Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study

AIM: To evaluate BAY 2433334, an oral activated factor XI (FXIa) inhibitor, in volunteers. METHODS: Phase 1 study of healthy men at a German centre. Part A: randomized, single‐blind, multiple dose‐escalation study of BAY 2433334 (25/50/100 mg once daily [OD]) vs. placebo. Part B: similar design to P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubitza, Dagmar, Heckmann, Michael, Distler, Jana, Koechel, Annemone, Schwers, Stephan, Kanefendt, Friederike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311154/
https://www.ncbi.nlm.nih.gov/pubmed/35014061
http://dx.doi.org/10.1111/bcp.15230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311154/
https://www.ncbi.nlm.nih.gov/pubmed/35014061
http://dx.doi.org/10.1111/bcp.15230

Ejemplares similares